Search
ALX Oncology Holdings Inc
ALXOAdd to Watchlist
2.070USD
+0.010+0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
278.50MMarket Cap
LossP/E TTM
More Details of ALX Oncology Holdings Inc Company
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
ALX Oncology Holdings Inc Info
Ticker SymbolALXO
Company nameALX Oncology Holdings Inc
IPO dateJul 17, 2020
CEOLettmann (Jason)
Number of employees80
Security typeOrdinary Share
Fiscal year-endJul 17
Address323 Allerton Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504667125
Websitehttps://alxoncology.com/
Ticker SymbolALXO
IPO dateJul 17, 2020
CEOLettmann (Jason)
Company Executives of ALX Oncology Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
263.61K
+19.23%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
78.00K
+3.85%
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
33.68K
-2.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Dr. Alan Sandler, M.D.
Dr. Alan Sandler, M.D.
Director
Director
--
--
Mr. Chris H. Takimoto, M.D., Ph.D.
Mr. Chris H. Takimoto, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
263.61K
+19.23%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
78.00K
+3.85%
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
33.68K
-2.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of ALX Oncology Holdings Inc?
The top five shareholders of ALX Oncology Holdings Inc are: Mr. Jason Lettmann
How many institutions hold shares of ALX Oncology Holdings Inc (ALXO)?
As of 2026Q1, 244 institutions hold shares of ALX Oncology Holdings Inc, with a combined market value of approximately 51.67M, accounting for 38.46% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3929077.00.